Diagnosis and Management of Refractory and Rare Moulds
Faster ID and AST revolution: How to Improve Antibiotic Use in the Critically Ill
COVID-19: impact on diagnostics and treatment
Streptococcus pneumoniae Serotyping and Antimicrobial Susceptibility: Assessment for Vaccine Efficacy in Canada After the Introduction of PCV-13: 10 Years of SAVE (2011-2020)
30 years in fulfilling unmet medical need for the evolving patient at risk for invasive fungal infections – Liposomal amphotericin B
Country data on AMR in India, Pakistan, Vietnam, Brazil, Mexico, Türkiye, Russia, Saudi Arabia and Kuwait
Future challenges in the management of serious infections
Syndromic diagnostics: better timing and better insights to deliver improvement to patient experience and outcomes
European surveillance of antimicrobial consumption: antibiotic consumption in the community, 1997–2017
Management of KPC-producing Klebsiella pneumoniae in clinical practice
Bridging the gap between human and animal surveillance data, antibiotic policy and stewardship: the EPI-Net and ARCH projects
Supplement 1 Survey of Antibiotic Resistance (SOAR) results 3: respiratory pathogen susceptibility
HepCare Europe: towards integrated hepatitis C care in the European Union
Ten years of the CANWARD Study (2007–2016)
Pharmacokinetic and pharmacodynamic analyses and dose rationale for lefamulin, a novel pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia
Standards of CARE in invasive fungal disease
The Accelerate Pheno™ system for organism identification and rapid MIC determination
The SAVE Study (2011–15): Streptococcus pneumoniae serotyping and antimicrobial susceptibility: assessment for vaccine efficacy in Canada
Survey of Antibiotic Resistance (SOAR) results 2: respiratory pathogen susceptibility
Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party
Beyond blood culture: whole blood diagnostics and antimicrobial stewardship
Appropriateness of antibiotic prescribing in English primary care
The future of echinocandin therapy
Towards short-course chemotherapy for pulmonary Mycobacterium avium disease based on PK/PD design
New trends and issues in invasive mould infections and diseases
Antifungal stewardship: existing framework and future perspectives
Survey of Antibiotic Resistance (SOAR) results: respiratory pathogen susceptibility
Epidemiology, diagnosis and treatment options for prosthetic joint infections
A multidisciplinary approach to managing invasive fungal disease
Efficacy and safety of tigecycline in clinical practice: experience from observational studies in Europe
Evolution of antimicrobial resistance in Canadian hospitals from 2007 to 2011: results of the CANWARD study
Combating antimicrobial resistance and healthcare-associated infections: the role of the Specialist Advisory Committee on Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI), 2007–2011
European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic consumption (1997-2009)
e-Bug: development and implementation of an antibiotic and hygiene resource for European schools
Changes and challenges in anti-Gram-positive chemotherapy: 10 years of clinical experience with linezolid
Changing needs of community-acquired bacterial pneumonia: experience with ceftaroline fosamil
Managing infections in critical care
Pathways for managing invasive fungal disease in immunocompromised patients
A new option for complicated skin and skin structure infections: experience with ceftaroline
Difficult to treat infections
Oseltamivir (Tamiflu) and its use against seasonal, avian and pandemic strains of influenza
Antimicrobial-resistant pathogens in animals and man: prescribing, practices and policies
Aspects of Antimicrobial Resistance
The changing face of febrile neutropenia-from monotherapy to moulds to mucositis
The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project 1999/2000-2006/7
Daptomycin development and clinical experience
Tigecycline, a therapeutic option from a new antimicrobial class (the glycylcyclines) in an era of increasing resistance
Difficult issues in mycology
Combating antimicrobial resistance: the role of the Specialist Advisory Committee on Antimicrobial Resistance, 2001-7
Supplement S1 Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005
The Alexander Project: the benefits from a decade of surveillance
Itraconazole and the management of systemic fungal infections
Dalbavancin, a novel second-generation lipoglycopeptide agent for the treatment of serious Gram-positive infections
Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic
PROTEKT US: results from the second year of this longitudinal surveillance study of antimicrobial resistance among respiratory tract pathogens isolated from paediatric and adult patients in the USA
Treatment of complicated community-acquired infections with ertapenem, the first Group 1 carbapenem
Augmentin® (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent
Managing skin and soft tissue infections: expert panel recommendations on key decision points
Vancomycin resistance in enterococci: a clinical challenge
Antimicrobial development: quinolones past, present and future
Linezolid: a novel oxazolidinone antimicrobial for the treatment of serious Gram-positive infections
Streptococcus pneumoniae: antimicrobials and ecology
PROTEKT: an innovative resistance surveillance programme for RTI pathogens
Cefpodoxime: fighting bacterial resistance
AmBisome: an international workshop
Structure and in vitro activity of telithromycin, the first member of a new class of antibacterials, the ketolides
Antimicrobial Susceptibility Testing: BSAC Working Party Report
Abstracts of the 7th International Symposium on New Quinolones
Herpesvirus infections: not just skin deep
Progress in the management of urinary tract infections
Global trends in resistance: initial results from the MYSTIC longitudinal surveillance programme
Gemifloxacin:potency and performance
Recent advances in the management of herpesvirus infections
Optimizing outcomes in the management of acute exacerbations of chronic bronchitis
Tonsillopharyngitis revisited
Zanamivir - a breakthrough in influenza
Quinupristin/dalfopristin - a novel approach for the treatment of serious Gram-positive infections
Levofloxacin: an extended spectrum 4-quinolone agent
Moxifloxacin: a new respiratory quinolone
Ten years of ciprofloxacin: the past, present and future
Fleroxacin, a long acting fluoroquinolone with broad spectrum activity
Spiramycin reassessed
Focus on ofloxacin—a new 4-quinolone antimicrobial agent
The impact of resistance on the selection of chemotherapy
Ciprofloxacin: quinolones in practice
The carrier state
Imipenem—assessing its clinical rôle
Perinatal and Neonatal Infections
